PTN Share Price

Open 0.59 Change Price %
High 0.59 1 Day 0.01 1.79
Low 0.56 1 Week -0.12 -17.39
Close 0.57 1 Month 0.05 9.62
Volume 1799011 1 Year -0.12 -17.39
52 Week High 0.90
52 Week Low 0.36
PTN Important Levels
Resistance 2 0.60
Resistance 1 0.59
Pivot 0.57
Support 1 0.55
Support 2 0.54
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
CVM 0.11 -38.89%
CVM 0.11 -38.89%
PLX 0.31 -44.64%
PLX 0.31 -44.64%
RBY 0.03 -70.00%
NAK 1.45 21.85%
NAK 1.45 21.85%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
CMFO 0.12 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RVP 1.30 -46.94%
PLX 0.31 -44.64%
PLX 0.31 -44.64%
CVM 0.11 -38.89%
CVM 0.11 -38.89%
QBC 0.20 -33.33%
More..

Palatin Technologies, Inc. (AMEX: PTN)

PTN Technical Analysis 3
As on 2nd Dec 2016 PTN Share Price closed @ 0.57 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.54 & Buy for SHORT-TERM with Stoploss of 0.57 we also expect STOCK to react on Following IMPORTANT LEVELS.
PTN Target for December
1st Target up-side 1.05
2nd Target up-side 1.21
3rd Target up-side 1.37
1st Target down-side 0.59
2nd Target down-side 0.43
3rd Target down-side 0.27
PTN Other Details
Segment EQ
Market Capital 26095102.00
Sector Healthcare
Industry Diagnostic Substances
Offical website http://www.palatin.com
PTN Address
PTN
4B Cedar Brook Drive
Cedar Brook Corporate Center
Cranbury, NJ 08512
United States
Phone: 609-495-2200
Fax: 609-495-2201
Interactive Technical Analysis Chart Palatin Technologies, Inc. ( PTN AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Palatin Technologies, Inc.
PTN Business Profile
Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. Its clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that is in Phase III clinical trials for the treatment of female sexual dysfunction. The company’s drug development programs comprise PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase 1 clinical trial for the treatment of cardiovascular and pulmonary indications; melanocortin receptor-based compounds for treatment of obesity; and Melanocortin receptor-1 agonist peptides for treatment of dermatologic and inflammatory disease indications. Palatin Technologies, Inc. has research collaboration and license agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. The company was founded in 1986 and is based in Cranbury, New Jersey.